Log In
Print
BCIQ
Print
Print this Print this
 

HLD-200

  Manage Alerts
Collapse Summary General Information
Company Highland Therapeutics Inc.
DescriptionModified-release formulation of the generic methylphenidate
Molecular Target Dopamine transporter ; Norepinephrine transporter
Mechanism of ActionDopamine and norepinephrine reuptake inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationAttention deficit hyperactivity disorder (ADHD)
Indication DetailsTreat ADHD
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today